BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 34497815)

  • 1. Prolonged Use of Proton Pump Inhibitors, but Not Histamine-2 Receptor Antagonists, Is Associated With Lower Bone Mineral Density in Males Aged Over 70.
    Gao S; Song W; Lin T; Chen W; He W; Wei Q; Li Z
    Front Med (Lausanne); 2021; 8():725359. PubMed ID: 34497815
    [No Abstract]   [Full Text] [Related]  

  • 2. Bone mineral density changes among women initiating proton pump inhibitors or H2 receptor antagonists: a SWAN cohort study.
    Solomon DH; Diem SJ; Ruppert K; Lian YJ; Liu CC; Wohlfart A; Greendale GA; Finkelstein JS
    J Bone Miner Res; 2015 Feb; 30(2):232-9. PubMed ID: 25156141
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Associations between Proton Pump Inhibitor and Histamine-2 Receptor Antagonist and Bone Mineral Density among Kidney Transplant Recipients.
    Lyu B; Hansen KE; Jorgenson MR; Astor BC
    Am J Nephrol; 2020; 51(6):433-441. PubMed ID: 32485707
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical Use of Acid Suppressants and Risk of Dementia in the Elderly: A Pharmaco-Epidemiological Cohort Study.
    Chen LY; Lin HJ; Wu WT; Chen YC; Chen CL; Kao J; You SL; Chou YC; Sun CA
    Int J Environ Res Public Health; 2020 Nov; 17(21):. PubMed ID: 33182362
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association between serum ferritin and bone mineral density in US adults.
    Peng P; Xiao F; Gao S; Fang W; Lin T; He W; Wei Q
    J Orthop Surg Res; 2022 Nov; 17(1):494. PubMed ID: 36384633
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative analysis of the risk of osteoporotic fractures with proton pump inhibitor use and histamine-2 receptor antagonist therapy in elderly women: A nationwide population-based nested case-control study.
    Park JH; Song YM; Jung JH; Han K
    Bone; 2020 Jun; 135():115306. PubMed ID: 32126312
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Does long-term medication with a proton pump inhibitor induce a tolerance to H2 receptor antagonist?
    Hashimoto H; Kushikata T; Kudo M; Hirota K
    J Gastroenterol; 2007 Apr; 42(4):275-8. PubMed ID: 17464455
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Esomeprazole use is independently associated with significant reduction of BMD: 1-year prospective comparative safety study of four proton pump inhibitors.
    Bahtiri E; Islami H; Hoxha R; Qorraj-Bytyqi H; Rexhepi S; Hoti K; Thaçi K; Thaçi S; Karakulak Ç
    J Bone Miner Metab; 2016 Sep; 34(5):571-9. PubMed ID: 26209167
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systematic reviews of the clinical effectiveness and cost-effectiveness of proton pump inhibitors in acute upper gastrointestinal bleeding.
    Leontiadis GI; Sreedharan A; Dorward S; Barton P; Delaney B; Howden CW; Orhewere M; Gisbert J; Sharma VK; Rostom A; Moayyedi P; Forman D
    Health Technol Assess; 2007 Dec; 11(51):iii-iv, 1-164. PubMed ID: 18021578
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neonatal Histamine-2 Receptor Antagonist and Proton Pump Inhibitor Treatment at United States Children's Hospitals.
    Slaughter JL; Stenger MR; Reagan PB; Jadcherla SR
    J Pediatr; 2016 Jul; 174():63-70.e3. PubMed ID: 27131401
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Associations between objectively-measured sedentary behaviour and physical activity with bone mineral density in adults and older adults, the NHANES study.
    Chastin SF; Mandrichenko O; Helbostadt JL; Skelton DA
    Bone; 2014 Jul; 64():254-62. PubMed ID: 24735973
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative risk of Clostridium difficile infection between proton pump inhibitors and histamine-2 receptor antagonists: A 15-year hospital cohort study using a common data model.
    Seo SI; You SC; Park CH; Kim TJ; Ko YS; Kim Y; Yoo JJ; Kim J; Shin WG
    J Gastroenterol Hepatol; 2020 Aug; 35(8):1325-1330. PubMed ID: 31970824
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reducing Unnecessary Acid Suppression Use in Hospitalized Patients: A Description of Targeted Strategies Implemented Across a Large Health System.
    Wiggins EH; Burgess LH; Kramer J
    HCA Healthc J Med; 2023; 4(2):125-137. PubMed ID: 37424981
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proton-pump inhibitor use is not associated with osteoporosis or accelerated bone mineral density loss.
    Targownik LE; Lix LM; Leung S; Leslie WD
    Gastroenterology; 2010 Mar; 138(3):896-904. PubMed ID: 19931262
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acid-suppressive medications and risk of bone loss and fracture in older adults.
    Yu EW; Blackwell T; Ensrud KE; Hillier TA; Lane NE; Orwoll E; Bauer DC
    Calcif Tissue Int; 2008 Oct; 83(4):251-9. PubMed ID: 18813868
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Maintenance Proton Pump Inhibitor Use Associated with Increased All-Cause and Cause-Specific Mortality in Sweden.
    Ngwenya S; Simin J; Brusselaers N
    Dig Dis Sci; 2023 Jun; 68(6):2252-2263. PubMed ID: 36629968
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proton pump inhibitors use and change in bone mineral density.
    Arj A; Razavi Zade M; Yavari M; Akbari H; Zamani B; Asemi Z
    Int J Rheum Dis; 2016 Sep; 19(9):864-8. PubMed ID: 27242025
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Histamine H2-Receptor Antagonist Use Is Associated With Lower Prevalence of Nonalcoholic Fatty Liver Disease: A Population-based Study From the National Health and Nutrition Examination Survey, 2001-2006.
    Shen H; Liangpunsakul S
    J Clin Gastroenterol; 2016 Aug; 50(7):596-601. PubMed ID: 26905606
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of daily treatment with acid suppressants for stress ulcer prophylaxis on risk of ventilator-associated events.
    Li X; Klompas M; Menchaca JT; Young JG
    Infect Control Hosp Epidemiol; 2020 Feb; 41(2):187-193. PubMed ID: 31818336
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of Histamine 2-receptor Antagonists and Proton Pump Inhibitors on the Pharmacokinetics of Gefitinib in Patients With Non-small-cell Lung Cancer.
    Yokota H; Sato K; Okuda Y; Kobayashi H; Takeda M; Asano M; Ito H; Miura M
    Clin Lung Cancer; 2017 Nov; 18(6):e433-e439. PubMed ID: 28579188
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.